Transposagen Announces New Product Offering: TGEM(TM) Genetically Modified Rat Models
LEXINGTON, Ky., April 22 /PRNewswire/ – Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it has added 170 genetically modified rats and related biomaterials to its database of laboratory rats with a genetic modification that can mimic a human disease. These animals are used by academic, pharmaceutical, and biotech scientists for drug discovery and development research and will be sold under Transposagen’s new TGEM(TM) Rat Models brand. A complete list of genetically modified and knockout rat models being offered by Transposagen is listed on their website – www.transposagenbio.com.
The new TGEM(TM) Rat Models include tumor suppressors, G protein-coupled receptors, and serotonin receptors. One showcase model is the Tumor Protein 53 (TP53) or p53 TGEM(TM) Rat Model. It is believed that more than 50 percent of human tumors contain a mutation or deletion of the TP53 gene. “A rat model lacking the function of this important gene will be a valuable tool for cancer biology and xenotransplantation studies,” said Dr. Eric Ostertag, President and CEO of Transposagen.
Other new TGEM(TM) Rat Models include:
- Rag1 – recombination activating gene 1 – immunodeficiency model
- BCRP (aka Abcg2) – Breast cancer resistance protein 1
- Mc4r – melanocortin 4 receptor – Obesity Model
- Ccr4 – C-C chemokine receptor type 4
- Cxcr2 (aka IL8rb) – High affinity interleukin-8 receptor B or chemokine (C-X-C motif) receptor 2
- IgE (aka Ighe) – Ig epsilon chain C region
- GPR – over 100 different G Protein-Coupled Receptors
“Major pharmaceutical companies, biotechnology companies, and academic researchers have not had access to rat models of these genes in the past,” said Dr. Ostertag. “Our new TGEM(TM) Rat Model product line coupled with our existing TKO(TM) Knockout Rat Model line further supports our reputation of being the worldwide leader in genetically modified rats.”
About Transposagen Biopharmaceuticals:
Transposagen Biopharmaceuticals, Inc., a Lexington, KY based company, is the worldwide leader in the creation of unique genetically modified rat models. The company’s signature products, TKO(TM) Knockout Rat Models and TGEM(TM) Rat Models, mimic human diseases and are used for drug discovery and development research. The company also creates custom transgenic rat models to customer specifications. The production of animal models is a $1.2 billion/year market and is expected to grow 12% annually through 2012. For more information, visit www.transposagenbio.com.
Contact: George Ward 201 W. Second St. Lexington, KY 40507 859-428-8561
SOURCE Transposagen Biopharmaceuticals, Inc.